Preparation and characterization of a novel agonistic anti-human death receptor 5 monoclonal antibody with apoptosis activity

Chinese Journal of Microbiology and Immunology

Volumn 26, Issue 7, 2006, Pages 632-636

  Liu, Guang Chao ^a   Ma, Yuan Fang ^b   Li, Shu Lian ^b   Bai, Hui Ling ^b   Zhang, Jun ^b   Lu, Feng ^b   Du, Yao Wu ^b   Zhao, Yue Ping ^b   Du, Jing Fang ^b  

^a HENAN UNIVERSITY   (China)

^b NONE

Author keywords

Apoptosis; Death receptor; Monoclonal antibody

Indexed keywords

AGAROSE; ANTIGEN; DEATH RECEPTOR 5; DNA FRAGMENT; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; LIPOCORTIN 5; MONOCLONAL ANTIBODY; PHOSPHATIDYLSERINE; PROTEIN G;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; ENZYME IMMUNOASSAY; GEL ELECTROPHORESIS; HYBRIDOMA; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN CONFORMATION; STAINING; WESTERN BLOTTING;

EID: 33750090076     PISSN: 02545101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3(6): 673-682.
2. Pan G, O'Rourke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TElAIL. Science, 1997, 276(5309): 111-113.
3. LeBlanc HN, Ashkenazi A. Apo2L/TRAIL and its death and decoy receptors. Cell Death Differ, 2003, 10: 66-75.
4. Ichikawa K, Liu W, Zhao L, et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocytotoxicity. Nat Med, 2001, 7(8): 954-960.
5. Ma Y, Yang D, Chen Y. Analysis of TRAIL receptor expression using a novel anti-TRAIL death receptor 5 monoclonal antibody. Chin Med J(Engl), 2003, 116(6): 947-950.
6. Truneh A, Sharma S, Silverman C, et al. Temperature-sensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem, 2000, 275(30): 23319-23325.
7. Lawrence D, Shahrokh Z, Marsters S, et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med, 2001, 7(4): 383-385.
8. Lee HW, Lee SH, Lee YW, et al. Homomeric and heteromeric interactions of the extracellular domains of death receptors and death decoy receptors. Biochem Biophys Res Commun, 2005, 330(4): 1205-1212.
9. Takeda K, Yamaguchi N, Akiba H, et al. Induction of Tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med, 2004, 199(4): 437-448.
10. Buchsbaum DJ, Zhou T, Grizzle WE, et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res, 2003, 9( 10 Pt 1): 3731-3741.
11. Choi C, Kutsch O, Park J, et al. Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells. Mol Cell Biol, 2002, 22(3): 724-736.
12. Ohtsuka T, Buchsbauni D, Oliver P, et al. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene, 2003, 22 (13): 2034-2044.